AI-powered insights from 8-K, 6-K, 10-K and 10-Q filings with category and key takeaways
Total
0
10-K
0
10-Q
0
8-K
0
6-K
0
13F
0
Other
0
Showing 30 of 16187 summaries
Filing ID: 791891 • Apr 3, 2026, 6:10 AM ET
Board declared a $0.50 per share dividend on Series C Preferred Shares (NYSE: SB.PR.C).
Board declared a $0.50 per share dividend on Series D Preferred Shares (NYSE: SB.PR.D).
Dividends cover the period from January 30, 2026 to April 29, 2026.
Safe Bulkers, Inc. declared a cash dividend of $0.50 per share on its 8.00% Series C and Series D Cumulative Redeemable Perpetual Preferred Shares, payable on April 30, 2026.
Filing ID: 791891 • Apr 3, 2026, 6:10 AM ET
Board declared a $0.50 per share dividend on Series C Preferred Shares (NYSE: SB.PR.C).
Board declared a $0.50 per share dividend on Series D Preferred Shares (NYSE: SB.PR.D).
Dividends cover the period from January 30, 2026 to April 29, 2026.
Safe Bulkers, Inc. declared a cash dividend of $0.50 per share on its 8.00% Series C and Series D Cumulative Redeemable Perpetual Preferred Shares, payable on April 30, 2026.
Filing ID: 791890 • Apr 3, 2026, 6:10 AM ET
Gross margin expanded, attributed to economies of scale from improved fixed cost absorption.
Selling and marketing expenses increased, primarily due to additional headcount from an acquisition.
Financial income decreased, driven by a reduction in the fair value of warrants, partially offset by higher interest income.
The company navigated a challenging year where strategic acquisitions drove operational expansion but resulted in increased financial strain, with management anticipating continued near-term operating losses as investments are made to support anticipated growth.
Filing ID: 791888 • Apr 3, 2026, 6:10 AM ET
The company reported a net income of R$15,988.4 million for 2025, a 7.7% increase from 2024, with net revenue decreasing 1.4% to R$88,242.5 million.
Global compensation paid to managers for 2025 was R$185,455,942.53, below the approved limit of R$249,548,559.00, with the difference attributed to projections for stock-based compensation and variable pay linked to performance goals.
The management proposes amendments to the company's bylaws to simplify the executive officer framework, including reducing the number of positions and creating a Corporate Affairs Vice President Officer role.
Ambev S.A. filed a 6-K/A on April 2, 2026, providing detailed management proposals for the 2026 shareholders' meetings, including executive compensation, bylaw amendments, and comprehensive financial and operational results for the fiscal year ended December 31, 2025.
Filing ID: 791889 • Apr 3, 2026, 6:10 AM ET
The 2026 Annual General Meeting is scheduled for May 19, 2026.
The company's 2025 Annual Report on Form 20-F is now available.
The meeting notice and annual report can be accessed via the company's website and attached links.
Golar LNG Limited announced that its 2026 Annual General Meeting will be held on May 19, 2026, and provided access to the meeting notice and the company's 2025 Annual Report on Form 20-F.
Filing ID: 791887 • Apr 3, 2026, 6:10 AM ET
The company has scheduled an Ordinary Shareholders' Meeting for April 30, 2026, with a distance voting deadline of April 26, 2026.
Key agenda items include approval of financial statements for the fiscal year ended December 31, 2025, and allocation of net profit for that year.
Shareholders will vote on electing 9 effective members and 2 alternates to the Board of Directors for a 3-year term ending in 2029.
Ambev S.A. has filed a Form 6-K/A containing a distance voting bulletin for its upcoming Ordinary Shareholders' Meeting scheduled for April 30, 2026, detailing the agenda and voting procedures.
Filing ID: 791884 • Apr 3, 2026, 6:10 AM ET
Net income improved 81.5% to -$17.3M from -$93.5M as losses narrowed substantially year-over-year.
Diluted EPS advanced 81.5% to -$0.96 from -$5.18, tracking the reduced net loss magnitude.
Net cash provided by operating activities rose to $50.3M from $17.9M, more than doubling to support liquidity.
FY2025 showed marked improvement with net loss narrowing 81.5% to -$17.3M from -$93.5M and diluted EPS improving 81.5% to -$0.96 from -$5.18, reflecting better loss absorption amid portfolio shifts, while operating cash flow strengthened significantly to $50.3M.
Filing ID: 791886 • Apr 3, 2026, 6:10 AM ET
Daniel Burton retired as CEO effective February 12, 2026, and from the Board effective February 17, 2026.
Burton to serve as Strategic Advisor from March 1, 2026, through December 31, 2026, with $10,000 monthly salary.
All unvested equity awards forfeited as of March 3, 2026.
Health Catalyst, Inc. entered into a transition agreement with former CEO Daniel Burton, appointing him as Strategic Advisor until December 31, 2026, following his retirement effective February 12, 2026.
Filing ID: 791885 • Apr 3, 2026, 6:10 AM ET
The alternate candidate for the Fiscal Council has been changed from Maria Salete Garcia Pinheiro to Vasco de Freitas Barcellos Neto.
Vasco de Freitas Barcellos Neto will run jointly with the previously nominated effective member, Aristóteles Nogueira Filho.
All votes previously cast for the original Fiscal Council candidate pair will be disregarded.
Ambev S.A. has updated its shareholder voting materials for the Annual General Meeting due to a replacement of the alternate candidate for the Fiscal Council, requiring shareholders to resubmit votes by April 26, 2026, if they wish to vote on this specific change.
Filing ID: 791883 • Apr 3, 2026, 6:10 AM ET
SPP issued default notices on March 30, 2026, under Amended and Restated Loan Agreement dated April 29, 2025, and June 18, 2024 Bridge Loan, citing covenant breaches.
SPP seeks to accelerate obligations, exercise pledges, and replace Lyneer management; Company contests as fabricated and debt satisfied via $77M shares.
Company filed lawsuit on April 1, 2026, in NY Supreme Court seeking preliminary injunction to block SPP's management, operational, and property actions.
Atlantic International Corp. received default notices from SPP Credit Advisors on March 30, 2026, under Lyneer term loan and bridge loan agreements, terminated COO Mathew Evelt for cause, and filed a lawsuit seeking injunction against SPP's control actions over Lyneer subsidiaries.
Filing ID: 791882 • Apr 3, 2026, 6:10 AM ET
Responding to news reports, Braskem confirms considering creditor protection mechanisms amid debt challenges.
Company engaged financial and legal advisors in September 2025 for capital structure assessment, process ongoing.
Progressing in formulating comprehensive restructuring plan and creditor negotiations.
Braskem S.A. clarifies it is evaluating creditor protection measures including judicial reorganization as part of ongoing capital structure optimization, with no final decision made.
Filing ID: 791880 • Apr 3, 2026, 6:10 AM ET
The Company received Nasdaq noncompliance notices for stockholders’ equity and bid price, reflecting material deviations from listing standards and introducing delisting risk.
A strategic shift toward asset disposition—evidenced by five property sales—was implemented to strengthen liquidity and reduce leverage exposure.
Debt maturity pressure intensified, with a significant portion of outstanding obligations scheduled to mature in 2026, necessitating near-term refinancing or restructuring actions.
FY2025 was defined by intensified financial stress and strategic recalibration, as the Company prioritized liquidity preservation and balance sheet stabilization amid heightened regulatory scrutiny and structural capital constraints.
Filing ID: 791881 • Apr 3, 2026, 6:10 AM ET
Q4 2025 revenue of $3.2 million was the strongest quarter of the year, approaching prior-year levels despite a streamlined organization.
Full-year 2025 gross margin improved to 40% from 38% in 2024, reflecting a more disciplined operating model.
The company ended 2025 debt-free with $14.39 million in cash and does not anticipate needing to raise capital for operations in the foreseeable future.
Super League Enterprise reported its Q4 and full-year 2025 financial results, highlighting a business transformation, a debt-free balance sheet with $14.39 million in cash, and a path toward cash basis EBITDA profitability by year-end 2026.
Filing ID: 791879 • Apr 3, 2026, 6:10 AM ET
Seasonal demand surges from business travel, Christmas, Carnival, and Brazilian school vacations drive revenue volatility tied to passenger traffic patterns.
Network rebuilding efforts contributed to passenger demand growth, supported by a more efficient next-generation fleet reducing fuel burn per ASK.
Fuel prices per liter declined excluding hedges, aiding cost management alongside fleet efficiency gains.
Azul S.A. navigated Chapter 11 restructuring and seasonal passenger demand pressures, with management pursuing capital structure restoration and liquidity improvements through a disciplined low-cost model amid network rebuilding efforts.
Filing ID: 791877 • Apr 3, 2026, 6:10 AM ET
Revenue increased 36.6% to $471.5M from $345.3M, driven by demand in Tactical Missiles and Integrated Defense Systems from advanced drone/loitering munitions technologies and higher GMLRS production rates.
Gross profit rose 43.8% to $190.0M with gross margin expanding to 40.3%, reflecting operating leverage from increased production volumes.
Operating income grew 14.8% to $72.9M, supported by volume growth and performance despite scaling pressures.
Revenue accelerated 36.6% to $471.5M on defense demand for tactical missiles and integrated systems, driving gross profit growth of 43.8% to $190.0M with margin expansion to 40.3%, though operating cash flow turned negative amid production scaling and growth investments.
Filing ID: 791878 • Apr 3, 2026, 6:10 AM ET
Registration Statement on Form 10 declared effective April 1, 2026, enabling spin-off of First Tracks Biotherapeutics from AnaptysBio.
Spin-off record date April 6, 2026; distribution effective April 20, 2026 at 12:01 a.m. New York time.
TRAX when-issued trading under TRAXv starts April 6, 2026; regular way on Nasdaq under TRAX from April 20, 2026.
First Tracks Biotherapeutics, Inc. announced SEC effectiveness of its Form 10 registration statement for the spin-off from AnaptysBio, Inc., with distribution of one TRAX share per ANAB share on April 20, 2026.
Filing ID: 791876 • Apr 3, 2026, 6:10 AM ET
The parties executed a waiver to extend the tender offer commencement date by ten days, moving the deadline from April 3, 2026, to April 13, 2026.
The extension modifies the original Agreement and Plan of Merger dated March 6, 2026, specifically adjusting the timeline in Section 1.1(a).
The waiver extends the commencement period to 26 Business Days after the Merger Agreement date, up from the original 20 Business Days.
Lisata Therapeutics and Kuva Labs agreed to extend the deadline to commence a tender offer under their merger agreement from April 3, 2026, to April 13, 2026.
Filing ID: 791875 • Apr 3, 2026, 6:10 AM ET
Restaurant-level EBITDA increased 138% to $1.7 million in 2025 from $723,828 in 2024, driven by cost controls and closure of underperforming locations.
Operating loss improved approximately 80% to $(364,585) in 2025 from $(1.8) million in 2024 despite lower revenue.
Net loss improved to $(687,839) or $(0.11) per share in 2025 compared to $(2.3) million or $(0.37) per share in 2024.
BT Brands reported improved 2025 financial results with a 138% increase in restaurant-level EBITDA to $1.7 million and an 80% reduction in operating loss, while advancing its proposed transformational merger with Aero Velocity to reposition as a technology platform.
Filing ID: 791875 • Apr 3, 2026, 6:10 AM ET
Restaurant-level EBITDA increased 138% to $1.7 million in 2025 from $723,828 in 2024, driven by cost controls and closure of underperforming locations.
Operating loss improved approximately 80% to $(364,585) in 2025 from $(1.8) million in 2024 despite lower revenue.
Net loss improved to $(687,839) or $(0.11) per share in 2025 compared to $(2.3) million or $(0.37) per share in 2024.
BT Brands reported improved 2025 financial results with a 138% increase in restaurant-level EBITDA to $1.7 million and an 80% reduction in operating loss, while advancing its proposed transformational merger with Aero Velocity to reposition as a technology platform.
Filing ID: 791873 • Apr 3, 2026, 6:10 AM ET
VIDA Global develops Vida Agent OS, a cloud platform for production-grade AI agents integrating with CRMs, telephony, and billing systems to automate tasks like lead qualification and appointment scheduling.
Channel-led distribution targets MSPs, SaaS vendors, and UCaaS/CCaaS platforms for embedding agents, supplemented by direct enterprise sales.
Offering: 3,333,334 Class A shares at $4.75 midpoint ($13.3M net proceeds), with 30-day overallotment for 500,000 more; dual-class structure gives founders 86.6% voting control post-IPO.
VIDA Global Inc. is building an AI Agent Operating System platform enabling businesses to deploy omnichannel AI agents for customer interactions across voice, messaging, email, and web. This S-1 filing supports its IPO of 3.33 million Class A shares at $4.75 midpoint, raising ~$13.3 million net proceeds amid early-stage losses and bitcoin treasury holdings.
Filing ID: 791874 • Apr 3, 2026, 6:10 AM ET
The Company secured a $5 million unsecured revolving loan facility with 12% per annum interest, increasing near-term liquidity without pledging assets.
$500,000 was drawn immediately on March 27, 2026, indicating urgent working capital needs and near-term cash deployment.
The facility matures on December 31, 2026 — a short 9-month term — implying refinancing risk or expectation of improved cash flow before year-end.
Healthier Choices Management Corp. entered into a $5 million unsecured loan agreement with Sabby Volatility Warrant Master Fund, Ltd. on March 27, 2026, bearing 12% annual interest, maturing December 31, 2026, and used for working capital; an initial $500,000 draw was made on the closing date.
Filing ID: 791871 • Apr 3, 2026, 6:10 AM ET
Net sales increased 17.7% to $117.8 million compared to the same quarter last year.
Net income surged 44.9% to $9.8 million, setting a new quarterly record.
Basic earnings per share rose 44.6% to $2.01 from $1.39 in the prior year quarter.
EACO Corporation reported record second quarter net sales of $117.8 million and all-time record quarterly net income of $9.8 million for the quarter ended February 28, 2026.
Filing ID: 791872 • Apr 3, 2026, 6:10 AM ET
MHCP Resolution No. 0666 dated April 1, 2026 authorizes USD 1.25 billion loan from specified lenders.
Loan term is 5 years, repayable in 4 equal installments with SOFR-based floating interest rate.
Proceeds repay USD 1.2 billion loan from March 20, 2024 for ISA acquisition and USD 50 million from April 25, 2025 loan.
Ecopetrol S.A. obtained authorization from the Ministry of Finance and Public Credit to execute a USD 1.25 billion loan for debt refinancing.
Filing ID: 791869 • Apr 3, 2026, 6:10 AM ET
Annual Meeting date set for May 8, 2026 — establishes timeline for governance actions and proxy process.
April 13, 2026 is the hard deadline for stockholder notices under Bylaws — late submissions will be invalid.
Universal proxy notice (Rule 14a-19) must be postmarked or electronically transmitted by April 13, 2026 — required for dissident director solicitations.
Galera Therapeutics, Inc. announced its Combined 2025 and 2026 Annual Meeting of Stockholders is scheduled for May 8, 2026, and established April 13, 2026 as the deadline for stockholder proposals, nominations, and universal proxy notices.
Filing ID: 791870 • Apr 3, 2026, 6:10 AM ET
Extended timely notice date to April 30, 2026 for shareholder proposals or director nominations.
Prior extension announced on March 26, 2026.
Submissions must be received at principal executive office with information per Amended and Restated Bylaws.
Spruce Power Holding Corporation extended the deadline for shareholder proposals and director nominations for its 2026 annual meeting to April 30, 2026, following a prior extension on March 26, 2026.
Filing ID: 791868 • Apr 3, 2026, 6:10 AM ET
The company's annual general meeting is scheduled for April 28, 2026, at 9:30 am Taipei time.
A resolution to increase authorized share capital will be voted on at the meeting.
The supplement corrects the proposed new authorized capital amount from US$125,000 to US$120,000.
Gogoro Inc. issued a supplement to correct a typographical error in the proposed share capital increase resolution for its upcoming annual general meeting.
Filing ID: 791868 • Apr 3, 2026, 6:10 AM ET
The company's annual general meeting is scheduled for April 28, 2026, at 9:30 am Taipei time.
A resolution to increase authorized share capital will be voted on at the meeting.
The supplement corrects the proposed new authorized capital amount from US$125,000 to US$120,000.
Gogoro Inc. issued a supplement to correct a typographical error in the proposed share capital increase resolution for its upcoming annual general meeting.
Filing ID: 791851 • Apr 2, 2026, 5:40 PM ET
Shareholders approved the Reincorporation Merger with TETE TECHNOLOGIES INC (Cayman), making it the surviving entity; this shifts corporate domicile and governance jurisdiction.
The Business Combination Proposal—merging Merger Sub into Holdings, making Holdings a wholly owned subsidiary of the Cayman entity—was approved unanimously, advancing the planned transaction.
PubCo’s post-combination name change from 'TETE TECHNOLOGIES INC' to 'Bradbury Capital Inc.' was approved, signaling rebranding aligned with the combined entity’s strategic identity.
Technology & Telecommunication Acquisition Corporation (TETE) held an extraordinary general meeting on March 30, 2026, where shareholders unanimously approved seven proposals—including reincorporation in the Cayman Islands, a business combination with Super Apps Holdings Sdn. Bhd., a name change to Bradbury Capital Inc., and director elections—enabling the proposed transaction to proceed.
Filing ID: 791851 • Apr 2, 2026, 5:40 PM ET
Shareholders approved the Reincorporation Merger with TETE TECHNOLOGIES INC (Cayman), making it the surviving entity; this shifts corporate domicile and governance jurisdiction.
The Business Combination Proposal—merging Merger Sub into Holdings, making Holdings a wholly owned subsidiary of the Cayman entity—was approved unanimously, advancing the planned transaction.
PubCo’s post-combination name change from 'TETE TECHNOLOGIES INC' to 'Bradbury Capital Inc.' was approved, signaling rebranding aligned with the combined entity’s strategic identity.
Technology & Telecommunication Acquisition Corporation (TETE) held an extraordinary general meeting on March 30, 2026, where shareholders unanimously approved seven proposals—including reincorporation in the Cayman Islands, a business combination with Super Apps Holdings Sdn. Bhd., a name change to Bradbury Capital Inc., and director elections—enabling the proposed transaction to proceed.
Filing ID: 791849 • Apr 2, 2026, 5:30 PM ET
Entered underwriting agreement on March 30, 2026 for 800,000 shares of 9.50% Series A Cumulative Redeemable Preferred Stock.
Public offering price $25.00 per share; underwriter purchase price $24.2125 except 100,000 affiliate shares at $25.00.
Gross proceeds $20 million, or $23 million if 120,000 share over-allotment option exercised.
Cantor Fitzgerald Income Trust entered into an underwriting agreement to issue 800,000 shares of 9.50% Series A Preferred Stock at $25.00 per share, expecting $20 million gross proceeds, closing April 8, 2026.